Safe Elections During COVID-19

The role of emergency medicine physicians and public health

by KRUTIKA KUPPALLI, MD; MADELINE GRADE, MD, MPH; AND MARY MERCER, MD, MPH

The COVID-19 pandemic has had downstream effects on global elections as governments are forced to balance health and safety concerns of the public against the need for maintaining a democratic process. To optimize the chance of a safe election from a public health perspective, all citizens must play a role in reducing community transmission.

Before Election Day
A low community transmission rate on election day will minimize the chance of exposure and infec-

CONTINUED on page 16

People line up in Arlington, Virginia, during first day of early voting, 2020 presidential election.

5 Emergency Physicians Vying for Congress

Meet your colleagues who are running for federal office this fall

by L. ANTHONY CIRILLO, MD, FACEP

On Nov. 3, 2020, a record number of emergency physicians will be on the ballot for election to the U.S. House of Representatives. Incumbents Mark Green, MD, and Raul Ruiz, MD, MPH, MPP, will be seeking reelection, while Ronny Jackson, MD; Rich McCormick, MD, MBA; and Hiral Tipirneni, MD, are seeking to increase the ranks of emergency physicians elected to federal office. Each of the emergency physicians running took some time to discuss their personal stories with me and answer a few questions to provide you with a sense of what they view as impor-

CONTINUED on page 7
Faster results, less waiting.

Improve ER patient flow with syndromic infectious disease testing from BioFire.

Patients often come to the ER with ambiguous, overlapping symptoms. You need fast, comprehensive lab results to clear up the confusion and keep the ER running smoothly. The BioFire® FilmArray® System utilizes a syndromic approach—simultaneously testing for different pathogens that can cause similar symptoms—to deliver actionable results in about an hour. The BioFire System is a simple, rapid test you can depend on to help you triage effectively and improve patient outcomes.

**Fast:** Rapid turnaround time facilitates efficient diagnosis and treatment decisions.

**Accurate:** Superior sensitivity and specificity for results you can trust.

**Comprehensive:** One test to check for a broad spectrum of pathogens—viruses, bacteria, parasites, fungi, and antimicrobial resistance genes—so you can determine the best course of action in the shortest amount of time.

Learn more about solutions from the leader in syndromic testing at biofiredx.com.

### BioFire® FilmArray® Panels

Tests available for your lab:

- **Respiratory**
  1 Test / 21 Targets / ~45 Minutes

- **Blood Culture Identification**
  1 Test / 27 Targets / ~1 Hour

- **Gastrointestinal**
  1 Test / 22 Targets / ~1 Hour

- **Meningitis/Encephalitis**
  1 Test / 14 Targets / ~1 Hour

- **Pneumonia**
  1 Test / 33 Targets / ~1 Hour

**Syndromic Testing:** The Right Test, The First Time.
Virtual Grand Rounds
Whatever your reason, we hope you’ll join us.

In November, you can choose from 14 different, free, virtual Grand Rounds on topics like COVID-19, physician wellness, airway, ultrasound, pediatrics, and international perspectives. Or for the chance to break from the daily grind and have fun with your tight-knit EM community.

In every Grand Round, you’ll be able to learn, connect, and have fun with your tight-knit EM community. Meetings will always include an expert presentation, followed by Q&A with the presenter and other experts in the field. Plus, you can ask questions in advance to help inform the presentation.

Virtual Grand Rounds are available starting Oct. 26.

Virtual Grand Rounds will cover:

• COVID-19
• Physician Wellness
• Airway
• Ultrasound
• Pediatrics
• International Perspectives

Register at www.acep.org/vGR

Get Your X-Waiver Training on Zoom
ACEP, in partnership with Providers Clinical Support System, is hosting free X-Waiver trainings done through the Zoom platform.

Visit www.acep.org/ed-x-waiver for more information.

Changes in Clinical Practice in the 2020 Elections and Beyond
ACEP, in partnership with Providers Clinical Support System, is hosting free X-Waiver trainings done through the Zoom platform.

Visit www.acep.org/ed-x-waiver for more information.

Virtual Grand Rounds Continue with Neurology Topics in November
ACEP’s Academic Affairs and Education Committee created the monthly Virtual Grand Rounds program in April as a way to provide free education for emergency physicians and residency programs during this time of social distancing. It allows you to track learner participation while engaging in Q&As with course faculty on different monthly topics. Once the sessions are complete, they are posted in the ACEP eCMO catalogue for online learning.

To register, visit www.acep.org/vGR.

Virtual Grand Rounds
• Nov. 18: Neurology
• Dec. 16: Cardiology

Navigate Election Season Through the ACEP 2020 Voter Resource Center
ACEP created a special tool to help you engage in the 2020 elections and beyond. Check out the 2020 Voter Resources for nonpartisan information where you can easily check if you are registered to vote, see how to vote early, or request an absentee ballot. You can also share with colleagues, family, and friends.

ACEP members can link to information about the influence and activities of the National Emergency Medicine PAC, ACEP’s political action committee. See page 5 for more 2020 election updates.

Get Your ED’s Pain and Addiction Care
We may be in the midst of a global pandemic, but the opioid epidemic isn’t going away. ACEP’s newest accreditation program, Pain and Addiction Care in the ED (PACED), is the nation’s only specialty-specific program that allows emergency departments to improve pain and addiction care. Elevate the quality of patient care with innovative treatments, alternative modalities, and impactful risk reduction strategies in a collaborative team setting, resulting in positive outcomes for your patients, families, health care workers, and communities. Learn more at www.acep.org/paced.

Jan. 27: Vulnerable Populations/Social Determinants of Health
Feb. 24: Simulation: OB Emergencies with EMR
ACEP Introduces Peer Support Project
ACEP recently introduced a new initiative, the ACEP Peer Support Project, designed to grow a network of peer supporters within emergency medicine while helping institutional break down barriers to care. Visit www.acep.org/peer-support-project to access peer support resources and join the SupportER list.

Final Countdown to ACEP Scientific Assembly Is On
WHO: Emergency physicians and other emergency care professionals across the globe! It’s easier than ever for our international audience to participate—no travel expenses, no hotels, no additional costs—so this is the year to give ACEP a try. And at a time when finances are tight for everyone, the value is there—just $3.86 per CME credit hour for ACEP members.

WHAT: ACEP20 promises an unconventional (BETTER!) experience, way beyond your customary Zoom calls. The lineup features special guests like Anthony Fauci, MD, Ibrahim Kendi, PhD; and Laurie Santos, PhD, plus EM experts including Amal Mattu, MD, FACEP; Michael Winters, MD, FACEP; Mari-anne Gausche-Hill, MD, FACEP, and more. Learn from more than 250 live and on-demand courses in 28 different clinical and practice tracks. Take home pearls that you can use in your practice on your next shift. Plus, attend social events to stay connected, from distance dining with EM luminaries to battling your peers in Fortnite and snapping stories over s’mores. Popular regular features will be available, too, including career assistance, an interactive exhibit hall, and more.

WHERE: Oct. 26–29, with access to the courses for three years. The 22 hours of live content can be claimed immediately following the conclusion of the event, commensurate with your participation. The 250-plus hours of on-demand content will also be available starting Oct. 26.

WHY: If you’ve been wondering what the ACEP20 Unconventional experience will look like, the preview at www.acep.org/sa/education/videos provides a sneak peek at the many ways you’ll be able to learn, connect, and have fun with your tight-knit EM community.

WHY: Because without you, ACEP just wouldn’t be the same. Your voices and participation keep the specialty moving forward—don’t be left behind. Go for the education, the community, the career advancement opportunity that can’t get any better than the chance to break from the daily grind and treat yourself to some “me time.” Whatever your reason, we hope you’ll join us. Register today at www.acep.org/acep20.
ACEP Surveys Members About COVID-19

Emergency physicians speak out on how the pandemic has changed their work environment

COVID-19 has changed life for emergency physicians on the front lines who are risking their own lives to combat the disease. ACEP has been actively advocating on your behalf to provide you with the tools and resources you need to safely do your job during the COVID-19 public health emergency. As part of that effort, ACEP staff, in conjunction with a subgroup of the ACEP Reimbursement Committee, designed a survey to help inform our advocacy strategy. The survey included 24 questions about the financial impact that COVID-19 has had on emergency medicine group practices and individual emergency physicians.

We received 197 responses, representing all emergency medicine group practice structures, group sizes, and historic volumes from across the country. The data confirmed anecdotal stories of the impacts on emergency medicine group practices, with almost all respondents reporting issues with the lack of reliable personal protective equipment and decreased volume and revenue.

Key findings on ED volumes and revenue are shown at right. Visit ACEPNow.com to see more results from the survey.


<table>
<thead>
<tr>
<th>Volume Decrease</th>
<th>Revenue Decrease</th>
<th>Individual Compensation Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25%</td>
<td>&lt;25%</td>
<td>≤10%</td>
</tr>
<tr>
<td>25–49%</td>
<td>25–49%</td>
<td>11–24%</td>
</tr>
<tr>
<td>50–74%</td>
<td>50–74%</td>
<td>25–49%</td>
</tr>
<tr>
<td>≥75%</td>
<td>≥75%</td>
<td>≥50%</td>
</tr>
</tbody>
</table>

Plants Don’t Growl, But You Wish They Did

by JASON HACK, MD, FACEP, FACMT

Question: What toxin makes this pretty plant one to watch for—and avoid?

Visit ACEPNow.com for the answer.
Experience an engaging, no-fluff, fast-paced update of the literature surrounding key emergency medicine topics by an experienced, energetic faculty of emergency medicine educators.

Now Available!

2020 Series

Unusual Antibiotic Side Effects
MRI vs. CT in the ED Setting
Challenges of Managing Pediatric UTIs
Emerging Issues in Anticoagulation
Chest X-Ray, Ultrasoundography, or CT? Headache - ACEP 2019 Guidelines
LPs in Febrile Infants 29-60 Days Old?
Suicidal Risk: Assessment and Intervention
Cardiovascular Pearls, 2019
DKA and Hyperglycemia Update
Sore Throat: Still Trying to Get It Right
Sexual/Racial/Ethnic Disparities in the ED
ACS & PE – ACEP 2019 Guidelines
Psychiatric Patients: Medical Evaluation
Sepsis 2019: Hot Off the Press
Challenges of Atrial Fibrillation - Part 1
Challenges of Atrial Fibrillation - Part 2
Otitis Media Doesn’t Cause Fever
Pears from ED Leadership Monthly
Pears from Risk Management Monthly
Urologic Imaging Guidelines
Pediatric Vomiting and Diarrhea
Trauma 2019: Hot Off the Press
Myths in Emergency Medicine
Myths in EMS Care
ATS/IDSA Updated Pneumonia Guidelines
Visual Diagnosis Challenges - Part 1
Visual Diagnosis Challenges - Part 2
Important Recent EM Literature - Part 1*
Important Recent EM Literature - Part 2*

*Topics listed with an asterisk (*) are 90-minute faculty panel discussions; all other topics are 30 minutes.

Buy the Home-Study Course Today at www.EMACourse.com/course or Call 1-800-458-4779 (9:00am-5:00pm ET, M-F)

Watch or Listen Instantly and Earn Up to 16.75 CME Credits!

Be Empowered to Avoid Clinical Situations That Put You and Your Patients at Risk with the High Risk Emergency Medicine Home-Study Course

Learn a Series of High-Yield Strategies to Limit Risks Associated With:

- Miscommunications
- Documentation Errors
- High Risk Chief Complaints
- Pass-On Errors
- Policies and Procedures Traps
- EMTALA Mistakes
- ... And Many More!

Buy the Home-Study Course Today at www.EMHighRisk.com/online or Call 1-800-458-4779 (9:00am-4:30pm ET, M-F)
Dr. Mary Nan S. Mallory tackles critical EM certification issues for ACEP Now

The American Board of Emergency Medicine (ABEM) has been transforming its approach to certification, a process that will culminate with the launch of MyEMCert next year. Mary Nan S. Mallory, MD, MBA, the new ABEM President, who was elected in August and serving for the 2020–2021 term, will be taking this multiyear process across the finish line.

Currently vice dean for clinical affairs and professor of emergency medicine for the department of emergency medicine at University of Louisville School of Medicine as well as an attending physician at the University of Louisville Hospital in Louisville, Kentucky, Dr. Mallory has been a member of the ABEM Board of Directors since July 2012 and was elected to the Executive Committee in 2019.

Dr. Mallory recently responded in writing to ACEP Now’s questions about her goals as ABEM President and the future of certification.

What are the priorities for ABEM this year?

Our number-one priority is to help physicians transition to a more continuous and lower-risk certification process. We will be continuing our conversations with physicians about changes to our certification process, such as online ConCert, the implementation of MyEMCert, and a virtual oral exam. We’ve designed these transitions based on what we’ve heard from physicians.

Why did ABEM go to a five-year certification cycle?

A number of factors contributed to the decision to change the certification cycle. It became apparent that smoothing out the costs of certification, launching MyEMCert, and shortening the 10-year certification cycle were all likely to occur very soon. The best way to accommodate these changes was to introduce the five-year certification cycle as soon as possible. Spacing out anticipated changes, such as an annual fee, MyEMCert, and a shorter cycle, would have created even greater complexity, which would have been difficult for physicians to navigate. In addition, if ABEM certification is going to stay a strong credential, we’ve got to reduce the time during which a certified physician could be not completing any certification activities.

The five-year certification cycle creates a process that encourages ongoing engagement to keep up with key advances in the specialty. By instituting the five-year cycle with the launch of MyEMCert in 2021 and by going to an annual fee, the number of times physicians have to adjust to change will be minimized. It also simplifies the continuing certification process and reduces the total number of requirements.

The move from 10-year to five-year certification—which simultaneously moving to an annual fee structure—does not come with any increased activity or additional costs.

Another factor ABEM took into account was the American Board of Medical Specialties Vision Initiative report that recommends certifying boards create a continuous certification process. A five-year cycle promotes more regular engagement in the process.

Finally, changing to a five-year cycle now allows physicians with certifications expiring in 2021 to recertify using MyEMCert. That gives nearly 3,000 physicians an opportunity they would not have had without going to a five-year certification cycle.

Also, why did ABEM choose to change to an annual fee?

The switch will allow physicians to avoid paying a one-time, large lump sum fee for the recertification exam (ConCert), which was $1,950. Instead, physicians will pay an annual fee that will approximate the same amount as physicians are now paying for continuing certification. And any physician who has paid more than $1,400 toward continuing certification activities will receive a check for the difference. (Refunds apply only to fees paid for successful completion of the ConCert Exam and Lifelong Learning and Self-Assessment tests; they will not apply to fees paid for retaking exams or for late fees.) None of these changes will result in increased revenue for ABEM. In fact, the five-year certification cycle will result in considerably less continuing certification revenue over the next decade.

Increasingly, ABEM directors heard from physicians that they wanted an annual fee structure. Physicians are then able to budget a lesser amount on an annual basis in their continuing professional development allocations instead of a large amount at one time when taking the exam.

What is the latest news on MyEMCert?

MyEMCert development continues at a rapid pace. Participants for the pilot have been selected, and the pilot begins this fall.

ABEM recently posted MyEMCert presentation scenarios—the core content for the specialty—on our website. We’ve also been developing key advances, areas in which there has been incomplete adoption of certain practices into emergency care. One example is the selection of acute ischemic stroke patients for potential endovascular reperfusion therapy. Some key advances are fairly recent, some less so, but the unifying theme is that we need to integrate these evolving practices into clinical care.

What new technology or apps are being developed or considered by ABEM to allow continuous interaction with the ABEM certification process from mobile devices?

The ABEM public website was redesigned a couple of years ago and is fully responsive, so it can be viewed on a mobile device. The new ABEM Reqs tool on the public website has been added so that you can check your requirements based on the year your certification expires. Although several app ideas have been explored, right now our resources are focused on the development of the MyEMCert platform. We hope to look into those ideas again after MyEMCert has launched and been fine-tuned. ABEM is also developing a virtual oral exam to accommodate physicians who were scheduled to take the exam in 2020.

What is ABEM doing to support physicians and destigmatize mental health challenges?

ABEM works with physicians who have had medical license issues as a result of mental health or substance disorders so that they don’t lose their certification. We supported 2019 Council Resolutions that addressed these concerns. We work with physicians in recovery programs to help them maintain their certification. ABEM believes that seeking assistance for mental health challenges is a sign of medical professionalism. Physicians are encouraged to contact ABEM prior to surrendering any state medical license to understand potential implications to their ABEM certification.

What is the latest news on MyEMCert?

MyEMCert development continues at a rapid pace. Participants for the pilot have been selected, and the pilot begins this fall.

What is ABEM doing about the issues of advanced practice providers?

ABEM recently issued a statement and press release stating that the delivery of emergency care is best led by ABEM-certified physicians. While ABEM honors the contributions to emergency care by other providers, the path to become a nurse practitioner or physician assistant is not equivalent to the complex training required to become an ABEM-certified physician. ABEM-certified physicians should be leading team-based care in the emergency department.

Finally, what would you like ACEP members to know about you that they might not know?

While my vitae reads of an academic physician, it’s my early career experiences in military medicine, as well as the years spent practicing emergency medicine in rural and community hospitals, that continue to inform and shape my service commitment to ABEM’s mission of ensuring the highest standards across our specialty. But there’s a life and lifelong learning to be had outside of the professional classroom, too. My husband and I enjoy long weekends hiking, wading, and roll-casting in the Great Smoky Mountains, where we are awed by the natural beauty of its streams and continually humbled by the innate brilliance of its wild trout.
Dr. Green first entered politics in 2012 by defeating Democratic incumbent Tim Barnes for a seat in the Tennessee State Senate. When Rep. Marsha Blackburn announced her candidacy for the United States Senate in 2018, Dr. Green announced his campaign to succeed her and was sworn into his first term of office in January 2019 and currently serves on the Foreign Affairs, Homeland Security, and Oversight and Reform committees. Dr. Green has sponsored legislation important to emergency medicine, especially in the areas of rural health and access to care.

1. “In the near term, the most important issue is obviously the COVID-19 pandemic. As a nation, we need to stay focused on addressing the challenges created by COVID. We need to continue to find innovative ways to address those challenges, like the creation of Operation Airbridge to improve the availability of PPE [personal protective equipment] and Operation Warp Speed to speed the develop of vaccines. We need to make sure that we have vaccines that are safe and that everyone who’s eligible gets vaccinated.”

2. “For me, running here in the Tennessee 7th district, the issues that are most important to my constituents are safety and security. People are concerned about local safety with rioting and protests but also still concerned about the global threats of terrorism and what a Russia/China alliance would mean to global security. The other issue that I am focusing on is how to improve our economy and reduce the national debt. [Also,] our fiscal House powers our national security, and we need to find ways to safely get our economy growing again.”

3. “We have to defend the doctor-patient relationship. In my role, as an emergency physician in Congress, is to educate the Congressional leaders and my colleagues on how legislation that only helps insurance companies will have devastating downstream effects on the stability of our health care delivery system in this country. I need the help of every emergency physician to amplify that message by taking the time to educate their individual members of Congress.”

Rear Admiral (Ret.) Ronny Jackson, MD (R, candidate TX-13)

Born and raised in the town of Levelland, Texas, Dr. Jackson graduated from Texas A&M University at Galveston and then attended medical school at the University of Texas Medical Branch. During his time in medical school, he served in the Navy Reserves and immediately upon graduating in 1991 began his active-duty military career as an officer in the U.S. Navy. In 2001, after five years in the Navy Diving community, Dr. Jackson returned to the Naval Hospital in Portsmouth, Virginia, to complete his residency in emergency medicine.

In 2006, while serving in Iraq, Dr. Jackson was selected as a White House physician in the George W. Bush administration. Over the next 14 years, he served three administrations includ-
ing serving as the director of executive health care for the president’s cabinet and senior staff, physician to the White House, and commanding officer of the White House medical unit. In January 2019, President Donald J. Trump appointed Dr. Jackson as assistant to the president and to the newly established role of chief medical advisor to the White House and the Executive Office of the President.

Dr. Jackson retired from the military as rear admiral on Dec. 1, 2019, with his last duty assignment at the White House.

1. “The most important issues facing the nation today are related to our safety and security, including our medical, economic, and physical safety. As a nation, we are being challenged by COVID-19 and its effect on all aspects of our daily life. We need to continue to rally all the resources at all disposal and work together to ensure that we get our country safely moving forward toward a return to normal.”

2. “In my campaign I am most passionate and excited about the opportunity to be a voice in D.C. that truly represents the people and being a voice for doing the right thing. I am not afraid to challenge my Congressional colleagues on both sides of the aisle to focus on passing thoughtful and sensible legislation that reflects what is best for the entire nation.

3. “As a member of Congress, I will work to ensure that insurance companies, especially large, for-profit companies, do not get to use their size and large profits to take advantage of frontline physicians or small and rural hospitals. As physicians, we also need to educate and remind our patients that we are their advocates in the healthcare policy debate. I will push for insurance companies to be more transparent in how health care premium dollars are being spent and how physicians are not the real problem in the increasing cost of health care in this country.”

Rich McCormick, MD, MBA (R, candidate GA-7)

Dr. McCormick is a graduate of Morehouse School of Medicine in Atlanta, where he was also student body president. He completed a residency in emergency medicine through Emory while training at Grady Hospital in Atlanta. He received his MBA from National University in La Jolla, California. With over 20 years in the U.S. Marine Corps and Navy, Dr. McCormick served in combat zones in Africa, the Persian Gulf, and Afghanistan. As a Marine, he flew helicopters and taught at Georgia Tech and Morehouse College as the Marine officer instructor. In the Navy, Dr. McCormick earned the rank of commander and served as the department head for the emergency medicine department in Afghanistan. At the completion of his military medicine career, Dr. McCormick returned to private clinical practice and currently practices at Gwinnett Medical Center and Northside Hospital in Georgia.

1. “I believe that we have to stop the march toward thinking that government is the solution to our problems. We have been asking government to fix the problems that they created. Government may be well intentioned, but too much government regulation has reduced physician compensation and given physicians less control over the most important part of health care...the doctor-patient relationship.”

2. “We need to keep government ‘right-sized’ by reducing government expansion and by expanding the private-sector economy by deregulation. Only by growing the private-sector economy can the United States be a country that people will want to come to because of economic opportunity, freedom, and the potential for upward mobility.”

3. “We must think outside the box and replace the antiquated system of health care insurance. The current system of health care insurance has no pricing transparency, limits flexibility, and creates no incentives for patient choice. By reducing government regulation, we can encourage more competition. We need to increase care delivery directly from physicians to patients, reducing the cost of intermediaries in health care delivery.”

Rep. Raul Ruiz, MD, MPH, MPP (D, incumbent CA-36)

Dr. Ruiz grew up in the community of Coachella, California, where both of his parents were farmworkers. Dr. Ruiz achieved his lifelong dream of becoming a physician through public education. After graduating from

---

Your NEMPAC 2020 Election Survival Kit

NEMPAC Community

When you contribute to NEMPAC, you join a group of like-minded emergency physicians who want to protect the future of emergency medicine, your patients, and your livelihood.

Friends in Congress

Want to see which candidates the NEMPAC Board has approved for support this cycle and the criteria used in their decision making? View a complete list on the NEMPAC site.

Access Pass to Congressional Members

Join the AACE 911 Legislative Grassroots Network by visiting the Advocacy tab at the top of the AACE.org homepage and receive access to special communications from our D.C. Government Affairs Team and our advocacy platform that will help you cultivate long-term relationships with legislators.

Voter Resources

Not sure if you’re registered to vote? Want to know who you are running in your area? Find it all on AACE.org’s 2020 Voter Resources tab on the AACE.org homepage.

Remember Election Day is November 3. Go vote!

---

Just as you are prepared 24/7 for everything in your emergency department, ACEP members can prepare for uncertain political times by engaging year round through NEMPAC.

When you contribute to NEMPAC, your $25 donation will not benefit or disadvantage you. By law, we may only use your contribution to support federal candidates if your contribution is made using a personal credit card or personal check. We are required to provide your employer name, your occupation, and to obtain an original signature of the ACEP member if contribution by credit card. NEMPAC encourages personal contributions. All non-personal contributions to NEMPAC are used to defray costs of educational activities for NEMPAC and other activities authorized under federal law.
Coached by Hiral Tipirneni, MD (D, candidate AZ-6)

Dr. Tipirneni came to America from India with her family at the age of three. She was raised in a suburb of Cleveland.

Following a childhood illness, Dr. Tipirneni was inspired to learn more about medicine. After graduating from public school, she eventually earned her medical degree through an accelerated, competitive program at Northeast Ohio Medical University. After serving as chief resident of the University of Michigan’s emergency medicine program, Dr. Tipirneni and her family moved to Arizona, where she worked in emergency departments at the Maricopa County Medical Center, Banner Thunderbird, and Abrazo Arrowhead hospitals—all while raising three children in the Arrowhead community.

After losing her mother and nephew to cancer, Dr. Tipirneni directed her passion and problem-solving skills to patient advocates in the fight to treat and cure breast cancer, evaluating and directing funding for cutting-edge cancer research. She now leads teams of researchers, clinicians, and patient advocates in the fight to treat and cure breast cancer, prostate cancer, and childhood leukemia.

1. “The loss of value and respect for science and data, because that affects how we address socioeconomic inequalities and injustice. Science has become demonized and politicized, which has led to [us] poorly responding to the pandemic.”

2. “No surprise…it’s health care. We need to promote policies that create healthy families, healthy communities, and a healthy nation. Good public policies must address the social determinants of health including mental illness, addiction, housing, and food security.”

3. “We need to rethink our reimbursement strategies to clinicians toward a system that is based more on value and less on volume of services and procedures performed. The federal government must enforce medical loss ratio requirements that insurers are required to meet.”

Dr. Cirillo serves on the ACEP Board of Directors and the NEMPAC Board of Directors. He still actively practices emergency medicine and serves as the director of government affairs for US Acute Care Solutions.
Abdominal compartment syndrome in the emergency department

Table 1: Grading of Intra-Abdominal Hypertension and Abdominal Compartment Syndrome

<table>
<thead>
<tr>
<th>IAH Grade</th>
<th>Intra-Abdominal Pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade I</td>
<td>12–15 mm Hg</td>
</tr>
<tr>
<td>Grade II</td>
<td>16–20 mm Hg</td>
</tr>
<tr>
<td>Grade III</td>
<td>21–25 mm Hg</td>
</tr>
<tr>
<td>Grade IV</td>
<td>&gt;25 mm Hg</td>
</tr>
<tr>
<td>Abdominal compartment syndrome</td>
<td>Sustained IAP &gt;20 mm Hg with new organ dysfunction</td>
</tr>
</tbody>
</table>

Adapted from Gottlieb et al.5

Table 2: Measuring IAP in Suspected ACS

1. Gather the following supplies: Foley catheterization kit, sterile gloves, 60-mL syringe filled with 25 mL of saline, curved hemostat, 1-L bag of fluid, and arterial line tubing and transducer kit (see Figure 1A).

2. Insert Foley catheter to drain all urine.

3. Place the patient in the supine position and provide appropriate analgesia.

4. Set up an arterial line, and prime with a 1-L bag of fluid.

5. Attach the stopcock to a 60-mL syringe filled with saline at the end of the arterial line tubing.

6. Clean the access port with an alcohol swab, and attach a three-way stopcock to the catheter access port (see Figure 1B).

7. Zero the pressure transducer at the level of the bladder, located at the iliac crest in the midaxillary line.

8. Clamp the drainage bag of the Foley catheter just distal to the aspiration port.

9. Instill a maximum of 25 mL of warm sterile saline into the bladder (see Figure 1C).

10. Turn the stopcock so the off position is now directed toward the 60 mL syringe. The syringe may now be removed.

11. Unclamp the distal Foley catheter to allow air in the proximal tubing to pass into distal tubing. The tubing should then be clamped again.

12. Before obtaining the IAP value, at least 30 seconds should pass with fluid in the bladder to ensure the detrusor muscle relaxes.

13. After this period, obtain the bladder pressure at end-exhalation.

14. Once the IAP is obtained, unclamp the Foley catheter.

LOW-PREVALENCE HIGH-RISK

A 62-year-old female patient presents with fever, cough, and an infiltrate on her chest radiograph. She receives intravenous fluids and antibiotics, but her symptoms worsen, eventually requiring intubation for respiratory decompensation and vasopressors for presumed septic shock. The intensive care unit is full, so the patient remains in the emergency department. During this time, her condition worsens, and she develops new renal and hepatic injury. You wonder if there is something you may be missing. Could this patient have abdominal compartment syndrome? If so, how do you test for it, and what are the next steps in management?

Discussion

Abdominal compartment syndrome (ACS) is a disease that can lead to significant morbidity and mortality. However, it is not often considered in the emergency department. With high rates of ED boarding in many areas, it is essential for the ED clinician to be aware of this disease and monitor for it.

ACS is similar to limb compartment syndrome in that there is excessive pressure within a closed space (ie, the abdominal compartment), resulting in damage to the surrounding structures. This exists as part of a continuum beginning with elevated intra-abdominal pressure (IAP) and ending with organ dysfunction (see Table 1). There are numerous causes of ACS, but they mainly fall into four general categories: reduced abdominal wall compliance (eg, abdominal surgery, obesity), increased abdominal contents (eg, large-volume ascites, hemoperitoneum), increased intraluminal contents (eg, ileus, gastroparesis), or capillary leak (eg, sepsis, pancreatitis).

Obtaining a relevant history may prove challenging because most patients with ACS are critically ill, and many are intubated. For patients who can provide a history, worsening abdominal pain, abdominal distension, or difficulty breathing (particularly when supine) may be reported. The physical examination is also limited in these patients; studies demonstrate a sensitivity of 40–60 percent and a specificity of 80–94 percent for ACS diagnosis. Abdominal distension and the absence of bowel sounds are associated with ACS, but their absence cannot exclude it. Therefore, clinicians should remember this condition for critically ill patients with worsening or refractory hypotension and those with new organ failure.

Laboratory studies may demonstrate evidence of severe organ dysfunction, including elevations in lactate, creatinine, and liver markers. If obtained, a computed tomography scan of the abdomen and pelvis may demonstrate an increased anteroposterior diameter, inferior vena cava collapse, diaphragm elevation, renal vessel compression, thickened bowel wall, pneumoperitoneum, or inguinal hernias bilaterally. However, neither the history and physical examination nor advanced imaging is sufficient to exclude the diagnosis. Therefore, clinicians who are concerned about ACS should measure the IAP (see Table 2).

Although multiple methods of IAP measurement have been proposed, intravesicular measurement generally preferred. As the name suggests, this measurement is obtained by placing a Foley catheter into the bladder. When measuring IAP, the patient should be supine and relaxed to avoid artificially increasing the IAP measurements. Ensure the patient’s pain is adequately controlled and measure the pressure at end-expiration. Clinicians should use warm saline to avoid detrusor muscle spasm, and no more than 25 mL of fluid should be...
KEY POINTS

1. Consider ACS in patients with risk factors who are persistently hypotensive or develop new organ injury.

2. Remember that the history and physical examination are unreliable. The preferred method for pre-operative diagnosis is to measure intra-abdominal pressure by using intra-vesicular pressure with a Foley catheter as a surrogate.

3. Management should include evacuating intraluminal and intraperitoneal contents, improving abdominal wall compliance, optimizing intravascular fluid therapy, and early surgical consultation for possible surgical decompression.

References


Waiver the Residents!

We can improve opioid use disorder management by changing how we train residents

by RACHEL HAROZ, MD; ALEXIS LAPIETRA, DO, FACEP; STEPHEN HOLTSFORD, MD; AND REUBEN J. STRAYER, MD

The last decade has witnessed a brutal toll of opioid-related suffering and deaths. Opioid addiction has shifted from a perceived moral failing confined to urban slums to one of accepted neurobiological disease pathology observed across geographic, racial, and socioeconomic lines. Medication-based treatment of opioid addiction reduces mortality and improves lives. Buprenorphine is safe and effective and can be initiated in the emergency department for patients with opioid use disorder (OUD). Significant barriers to treatment remain, however.

While buprenorphine can reduce mortality by two-thirds, only one out of three patients with OUD have access to this medication. Opioid use disorder has the highest short-term mortality of any acute disease we routinely treat in the emergency department, and it often occurs in young, otherwise healthy patients who, if moved to recovery, will go on to live long and productive lives. Due to stigma, however, addiction and addiction treatment have been sidelined away from the rest of medicine. While we can have a substantial impact on our patients with OUD, we are much more comfortable treating heart disease, stroke, and sepsis. The work to bring OUD recognition and treatment into the purview of emergency medicine starts with the way we teach it to emergency medicine residents.

New Paradigm for a New Generation

Residency training is structured to systematically address the pathology and treatment of disease encountered in the emergency department. Residents are trained to make lifesaving diagnoses and perform complex procedures. This training gives little consideration to where the resident will eventually practice; the prevailing paradigm is that all emergency department doctors should be able to treat all life-threatening diseases in any acute care setting.

As opioid deaths have skyrocketed over the last decade, emergency medicine residencies have largely continued to treat addiction according to the principles espoused since the specialty’s inception: provide a referral to addiction services and discharge the patient with a slap on the back. The data supporting the initiation of buprenorphine in the emergency department are clear and compelling, but most current EM residents have not received training on its use. This familiarity within the emergency medicine physician’s scope of practice, we continue the sad tradition of inadequate access and perpetuate stigma. We convey the message that OUD as a disease is not worth our time or effort.

Addiction training should start with equipping all emergency department residents with a Drug Enforcement Administration (DEA) X-Waiver so they can prescribe buprenorphine, and this should be incorporated into the standard curriculum of emergency medicine residency training. This training can be easily incorporated into weekly didactics, and the certification never expires. Equipping our future emergency department physicians with the ability to treat the life-threatening disease of opioid use disorder is just good medicine. We must be part of the solution.

References


DR. HAROZ is a physician at Cooper University Healthcare in Camden, New Jersey. DR. LAPIETRA is a physician at St. Joseph’s Health in Paterson, New Jersey. DR. HOLTSFORD is a physician at Northwestern Medicine Delnor Hospital in Geneva, Illinois. DR. STRAYER is a physician at Maimonides Medical Center in Brooklyn, New York.
Compiled by Shuhan He, MD, an emergency physician at the Center for Innovation in Digital HealthCare, and Alister Martin, MD, MPP, faculty at the Center for Social Justice and Health Equity at Massachusetts General Hospital in Boston.

Visit ACEPNOW.com for the sources of these statistics.

By the Numbers
X-WAIVER

HEALTH CARE WORKERS

1,200

signed up for the largest ever remote DEA X-Waiver session

3 STATES WITH UPCOMING GET WAVERED REMOTE COURSES
(California, Michigan, Ohio)

In just one May X-Waiver course,

814

HEALTH CARE WORKERS

started the waiver process

THE GOAL:

10K

HEALTH CARE WORKERS
WAIVERED BY 2022

UNPRECEDEDENT TIMES • UNCONVENTIONAL ACEP20 • JOIN US ONLINE IN 2020

OCTOBER 26-29 • 2020

THERE’S STILL TIME TO REGISTER!

Only a Few Days Left
To Join Thousands of Your Colleagues for ACEP20

Connect with personal chat rooms, coffee lounges and reunions

Learn with 250+ course presented by the leaders in EM

Celebrate your achievements this year with happy hours and special events

Access the courses with Virtual ACEP for 3 years

Get the science with Research Forum presentations

Learn more and register today at acep.org/acep20

Approved for AMA PRA Category 1 Credit™

American College of Emergency Physicians®
ADVANCING EMERGENCY CARE

OCTOBER 2020 ACEPNOW 13
Bad news for SARS-CoV-2 and his pals.


Right now, SARS-CoV-2 is everyone’s top suspect, but respiratory bugs can cause similar, overlapping symptoms. Now you can test for 22 common respiratory pathogens, including SARS-CoV-2, with the BioFire® Respiratory 2.1 (RP2.1) Panel—now available under an FDA Emergency Use Authorization.\(^3\)

Syndromic testing means all it takes is one test and just 45 minutes to round up SARS-CoV-2—and all the other usual respiratory suspects. Rapid answers on a broad range of pathogens can inform patient management and alleviate patients and staff alike. What’s your frontline solution into respiratory season and beyond?

To learn more, visit biofiredx.com/Covid-19
BioFire® Respiratory 2.1 (RP2.1) Panel
1 Test. 22 Targets. ~45 Minutes.

BioFire RP2.1 Panel Targets

**VIRUSES**
- Adenovirus
- Coronavirus 229E
- Coronavirus HKU1
- Coronavirus OC43
- Coronavirus NL63
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H3
- Influenza A/H1-2009
- Influenza B
- Parainfluenza Virus 1
- Parainfluenza Virus 2
- Parainfluenza Virus 3
- Parainfluenza Virus 4
- Respiratory Syncytial Virus

**BACTERIA**
- Bordetella parapertussis
- Bordetella pertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae

Sample Type: nasopharyngeal swab in 0.3 mL of transport medium

Overall 97.1% sensitivity and 99.3% specificity (prospective specimens)²
SARS-CoV-2 98.0% sensitivity and 100% specificity (archived specimens)³
SARS-CoV-2 100% PPA and 100% NPA (contrived specimens)⁴

1. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
2. Based on the prospective portion of the clinical study for the BioFire FilmArray Respiratory 2 (RP2) Panel.
4. Based on the contrived specimen study in the BioFire Respiratory 2.1 (RP2.1) Panel EUA submission.
tion in voters, poll workers, and election officials. Local public health departments are promoting this objective through three strategies: Behavior Registrar modification, disease surveillance, and outbreak control. Behavioral modification guidelines target preventing disease transmission and include recommendations for individuals and organizations. These include isolation and quarantine of people who have symptoms of COVID-19, such as fever, cough, or shortness of breath, hand hygiene, respiratory etiquette (covering coughs or sneezes), mask wearing, and when interacting with people outside of one's immediate household, and maintaining physical distancing of six feet or greater with others.

Disease surveillance requires a robust testing program with adequate supply of materials, efficient laboratory test turnaround times, and delivery of results to patients and health care workers. Stratification of data by demographic factors including age, race/ethnicity, and neighborhood will help communities respond to rises in disease transmission rates. Public health departments should partner with a variety of community stakeholders to promote active engagement in testing efforts.

When a case is identified through testing, successful outbreak control requires case investigation and contact tracing (CI/CT). Although time-intensive, effective CI/CT programs have been shown to reduce the reproductive rate of the virus (the R) from local values of more than 2.0 to 0.4 by offering two key interventions. First, a case investigator should educate an infected individual on how to self-isolate for up to 14 days to decrease transmission to others. Successful isolation may require referrals to social services such as isolation and quarantine hotels, food delivery programs, or temporary income assistance. The second important step, contact tracing, involves determining who else in a patient's household, workplace, and community may have been a “close contact” (a person who was exposed to the person for greater than 15 minutes). Close contacts are contacted by the department of public health and are confidentially advised of an exposure; assessed for symptoms; and advised for quarantine, self-monitoring, or testing, depending on the time since exposure and symptoms.

Role of Emergency Physicians

Emergency physicians can play a role in helping patients stay healthy and vote safely this November through both clinical care and communication. Most directly, our duty as frontline physicians involves ensuring that members of higher-risk groups (e.g., older individuals, immunocompromised individuals, residents of group living facilities, and essential workers) are appropriately tested leading up to and following the election. This includes excellent history-taking around symptoms and potential exposures as well as identifying close contacts so cases can be identified early and spread of disease is mitigated. Beyond history and workup, communication is crucial. According to a large, nationally representative survey released in April 2020, trust in hospitals and physicians during COVID-19 is high, particularly relative to other institutions and groups.5 We are important sources of information and education regarding public health guidelines such as hand hygiene, face masks, and social/physical distancing. We can help patients understand what to expect if they undergo testing and link to appropriate resources so they can safely isolate.

As various state and local elections officials adapt their voting strategies this year, we can inform our patients about their local voting options. Not only are these discussions clinically relevant, they have legal and logistical precedent. The 1993 National Voter Registration Act allows any institution providing “public assistance,” including hospitals, to participate in nonpartisan voter registration and information sharing. National organizations such as VOTE! and Community Health Vote empower thousands of health care workers to engage patients in conversations about voter registration and safe voting plans.

How to Have Safe In-Person Voting

Healthy and safe elections are a priority for all Americans and our democracy. Clear, nonpartisan, and evidence-based recommendations are needed for public health and elections officials to follow as they develop policies and procedures in advance of election day.6

1. Early and mail-in voting can help reduce crowd volumes, reduce in-person contact, and ultimately reduce transmission risk. Some individuals will need to vote in person, and for these people, a uniform, evidence-based public health message about what to expect at polling sites is important. This messaging should include using hand hygiene, maintaining physical distance of at least six feet between individuals, and wearing face masks that cover the nose and mouth to prevent the transmission of COVID-19. For safe in-person elections to occur, elections officials should increase the number of polling locations to avoid overcrowding and relocate polling locations to large, well-ventilated areas to allow for appropriate physical distancing. Localities should aim to have polling locations in large, well-ventilated sites such as sports arenas, concert venues, convention centers, school gymnasiums, or community recreation centers. For optimal infection control, voting locations should conduct check-in activities outdoors (or permitting), establish separate points of entry and exit for voters, and have unidirectional flow of foot traffic. Additionally, ventilation should be optimized by avoiding recirculation of potentially contaminated air.

2. Polling locations should have adequate supplies to support healthy hygiene for voters, poll workers, and elections officials. This includes hand sanitizer with at least 60% alcohol, soap, paper towels, no-touch trash cans, disinfectant wipes, and face masks. Polling sites should be thoroughly cleaned with an Environmental Protection Agency–approved disinfectant prior to opening on election day, with special attention given to high-touch surfaces, such as poll worker stations and voting booths. These areas and any reusable items should be routinely disinfected throughout the day. Hand sanitizer should be available at entrances, exits, and each step of the voting process for voters and poll workers. Polling locations should have plexiglass barriers between voters and workers at registration tables.

3. In addition, voters should expect to arrive at polling locations early and expect to wait. They can minimize their time and risk of COVID-19 by filling out a sample ballot prior to election day to make in-person voting time-efficient, vote during an off-peak time, and come to the polls wearing a facemask.

4. Election day does not happen without poll workers, and wide-scale campaigns to recruit extra workers may reduce the burden of individual exposures to others. Poll workers should be trained in the appropriate use of personal protective equipment and offered free testing for COVID-19 before and after their shifts at the polls. Any individual concerned about their personal risk for COVID-19 as a poll worker should consult their physician.

5. COVID-19 is the greatest social, health, and economic threat of our generation. As we approach Nov. 3, it is critical that local communities, health care workers, and public health department workers work together to minimize the risk of COVID-19. We have the knowledge and scientific evidence to have a safe election. Now is the time to implement policies and practices and keep our patients informed about them. No person should have to choose between the right to vote and the right to be healthy.

References


KEY POINTS

- To optimize the chance of a safe election from a public health perspective, all citizens must play a role in reducing community transmission of COVID-19. This includes using hand hygiene, wearing face masks that cover the nose and mouth, and maintaining physical distance of at least six feet between individuals.

- To lower community transmission rates of COVID-19 in advance of election day, public health officials can promote behavior modification, disease surveillance, and control of COVID-19.

- By ensuring appropriate individuals are tested for COVID-19 and through the education of patients, emergency physicians play a key role in helping patients stay healthy so they can vote safely on election day.

- For safe in-person elections to occur, the number of polling locations should be increased to avoid overcrowding and polling locations should be relocated to large, well-ventilated areas to allow for appropriate physical distancing.

- On election day, voters should arrive to the polling location alone, arrive early, and expect to wait.

- Wide-scale campaigns to recruit extra poll workers from low-risk groups must be implemented and these individuals should be offered free testing for COVID-19 before and after their shifts at polling stations.

In Arlington, Virginia, people line up and look at sample ballots during first day of early voting, 2020 presidential election.
Congratulations to the 2020 recipients of the College’s most prestigious awards. These recipients will be recognized during ACEP20 Unconventional with video tributes and acceptance speeches.

John G. Wiegenstein
Leadership Award
David C. Seaberg, MD, CPE, FACEP

Dr. Seaberg graduated with a BA in chemistry from Washington University in St. Louis, attended the University of Minnesota School of Medicine, and completed his emergency medicine residency at the University of Pittsburgh.

His leadership roles include research director at the University of Pittsburgh, residency director at the University of Florida, Jacksonville, and chair of emergency medicine at the University of Florida, Gainesville. In 2017, he became the inaugural dean at the University of Tennessee College of Medicine Chattanooga, also serving as chair of emergency medicine and senior vice president of physician integration at the Erlanger Health System.

Dr. Seaberg was elected to the ACEP Board of Directors and became President in 2011 and Chair of the Board in 2012. He also helped US Acute Care Solutions reestablish the Summa Department of Emergency Medicine as chair and Executive Vice President.

James D. Mills
Outstanding Contribution to Emergency Medicine Award

John J. Rogers, MD, CPE, FACEP

Dr. Rogers graduated from Augustana College in Rock Island, Illinois, with a degree in biology and completed a surgical internship at the University of Iowa College of Medicine, and a surgical residency at the Medical Center of Central Georgia in Macon.

He began working in emergency departments in 1979 part-time and full-time in 1994. Dr. Rogers is Vice President and a member of the Board of Directors of the Bibb County Medical Society. He is a member of the Medical Association of Georgia’s Council on Legislation and a delegate to the Medical Association of Georgia House of Delegates. He is ED medical director at Coliseum Northside in Macon.

Dr. Rogers held several leadership roles in the Georgia Chapter of ACEP, including chapter President, and remains on the Board of Directors. He has served on several ACEP committees, chaired the Rural and Workforce Sections, and founded the Telemedicine Section. He was elected to the ACEP Board of Directors in 2011 and served two terms.

John A. Rupke
Legacy Award
Peter M. Fahrney, MD, FACEP(E)

Dr. Fahrney was a Seabee medical officer in Vietnam, working as a volunteer in the 3rd Marine Division MASH unit, and later was appointed medical officer for the 12th Battle of Seabees that made up the Atlantic Command (COMCLANT).

Dr. Fahrney took a position at Suburban Hospital in Bethesda, Maryland, where he remained for his 32-year career. He attended meetings in Arlington and Alexandria, Virginia, with the “founding fathers” of emergency medicine. Soon, ACEP was established. He joined ACEP in 1969, serving in many capacities. At the first meeting of the Council in Washington, D.C., in 1973, Dr. Fahrney was selected as the first Speaker of the Council and presided over its tumultuous first meeting. He was also elected that year to the Board of Di-

INSTRUCTIONS AND USAGE

NUZYRA® is a tetracycline-class antibiotic indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:

- Community-Acquired Bacterial Pneumonia (CABP) caused by the following: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.
- Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following: Streptococcus pyogenes, Streptococcus agalactiae, and Haemophilus influenzae, among others.

ACUTE HYPERSENSITIVITY REACTIONS: Patients with a history of sensitivity to tetracyclines may develop a skin rash. Allergic reactions to tetracyclines have been reported. Patients who develop an allergic reaction to any of the above drugs should not be retreated with a similar class of antibiotics.

I.M. HYPERSENSITIVITY REACTIONS: Symptoms may include pruritus, rash, urticaria, angioedema, and anaphylaxis. In patients who develop an allergic reaction, antimicrobial therapy should not be reinitiated.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NUZYRA® is contraindicated in patients with known hyperactivity to tetracyclines or other tetracycline-class antibiotics, or of any of the excipients.

WARNINGs AND PRECAUTIONS

Mortality was observed in the CABP clinical trial with eight deaths (3%) occurring in patients treated with NUZYRA® compared to four deaths (2%) in patients treated with moxifloxacin. The cause of the mortality in patients treated with NUZYRA® was unexplained.

The use of NUZYRA® in CABP patients, particularly in those at higher risk for mortality, should be reevaluated.

The use of NUZYRA® in patients with a history of gastrointestinal disease, including peptic ulcer disease, should be avoided.

The use of NUZYRA® in patients with pre-existing renal impairment or renal dysfunction should be avoided.

The use of NUZYRA® in patients with a history of severe renal impairment or renal dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing hepatic impairment or hepatic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing lung impairment or lung dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing cardiac impairment or cardiac dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing neurologic impairment or neurologic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing psychiatric impairment or psychiatric dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing endocrine impairment or endocrine dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing hematologic impairment or hematologic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing gastrointestinal impairment or gastrointestinal dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing musculoskeletal impairment or musculoskeletal dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing dermatologic impairment or dermatologic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing ophthalmologic impairment or ophthalmologic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing otologic impairment or otologic dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing genitourinary impairment or genitourinary dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing respiratory impairment or respiratory dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing integumentary impairment or integumentary dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing constitutional impairment or constitutional dysfunction should be avoided.

The use of NUZYRA® in patients with pre-existing general impairment or general dysfunction should be avoided.

NUZYRA® is not intended for use in patients with renal impairment.

DRUG INTERACTIONS

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA®.

Absorption of tetracyclines, including NUZYRA®, is impaired by antibiotics containing aluminum, calcium, magnesium, or tetracycline; calcium carbonate; and iron-containing preparations.

USE IN SPECIFIC POPULATIONS

Lactation: Breastfeeding is not recommended during treatment with NUZYRA®.

DRUG INTERACTIONS

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA®.

Absorption of tetracyclines, including NUZYRA®, is impaired by antibiotics containing aluminum, calcium, magnesium, or tetracycline; calcium carbonate; and iron-containing preparations.

USE IN SPECIFIC POPULATIONS

Lactation: Breastfeeding is not recommended during treatment with NUZYRA®.

NUZYRA® is not intended for use in patients with renal impairment.

© 2018 Paratek Pharmaceuticals, Inc. All rights reserved.
NUZYRA® and its logo are registered trademarks of Paratek Pharmaceuticals, Inc.
NUZYRA® is a trademark of Paratek Pharmaceuticals, Inc.
US-N-022N 08/19

Please see Brief Summary of Full Prescribing Information on the following pages.
NUZYRA® (omadacycline) injection for intravenous use
NUZYRA® (omadacycline) tablets, for oral use

**BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION**

For complete details, please see Full Prescribing Information.

**INDICATIONS AND USAGE**

Community-Acquired Bacterial Pneumonia (CABP)

NUZYRA® is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.

**Acute Bacterial Skin and Skin Structure Infections (ABSSSI)**

NUZYRA® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.

**USAGE:**

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA® and other antibacterial drugs, NUZYRA® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the selection of an antibacterial therapy.

**CONTRAINDICATIONS:** NUZYRA® is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the components of the tablet or injection.

**WARNINGS AND PRECAUTIONS**

**Mortality Imbalance in Patients with Community-Acquired Bacterial Pneumonia**

Mortality imbalance was observed in the CABP clinical trials with eight deaths (2%) occurring in patients treated with NUZYRA® compared to four deaths (1%) in patients treated with moxifloxacin. All deaths, in both treatment arms, occurred in patients ≥65 years of age. Most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly those at higher risk for mortality.

**Throat Discoloration and Enamel Hypoplasia**

The use of NUZYRA® during tooth development (full teeth of pregnancy, infancy and childhood) up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the tetracycline-class drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported with tetracycline-class drugs. Advise the patient of the potential risk to the fetus if NUZYRA® is used during the second or third trimester of pregnancy.

**Inhibition of Bone Growth**

The use of NUZYRA® during the second and third trimesters of pregnancy, infancy and childhood (up to the age of 8 years) may cause severe reversible inhibition of bone growth. All tetracyclines form stable chelates in the same bone-forming tissue. A decrease in fibular growth rate has been observed in premature infants given tetracycline in doses of 25 mg/kg every 6 hours. The enamel was shown to be reversible when the drug was discontinued. Advise the patient of the potential risk to the fetus if NUZYRA® is used during the second or third trimester of pregnancy.

**Tetracycline-Class Effects**

Most Common Adverse Reactions: Table 4 lists the most common adverse reactions associated with NUZYRA® administration.

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>NUZYRA (N = 388)</th>
<th>Moxifloxacin (N = 388)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Constipation</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Increased hepatic aminotransferase activity</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Gamma-glutamyl transferase increased</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Transaminase increased</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Blood pressure decreased</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>2%</td>
<td>3%</td>
</tr>
</tbody>
</table>

**Adverse Reactions in Patients Receiving NUZYRA® in Trial 1**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>N = 325</th>
<th>N = 325</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality imbalance</td>
<td>8%</td>
<td>1%</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>8%</td>
<td>1%</td>
</tr>
<tr>
<td>Mortality imbalance in patients with CABP randomized to NUZYRA®</td>
<td>7%</td>
<td>1%</td>
</tr>
<tr>
<td>All-cause mortality in patients with CABP randomized to NUZYRA®</td>
<td>7%</td>
<td>1%</td>
</tr>
</tbody>
</table>

**Development of Drug-Resistant Bacteria**

Preclinical NUZYRA and NUZYRA in the mouse model demonstrated that broad-spectrum antibacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

**ADVERSE REACTIONS:**

The following clinically significant adverse reactions occurred with 2% or more of patients treated with NUZYRA in the clinical trials:

- Hypersensitivity Reactions
  - Inhibition of Bone Growth
  - Tetracycline-Class Effects

**Clinical Trials Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

**Preclinical Safety Evaluation of NUZYRA®**

NUZYRA® was evaluated in two Phase 3 clinical trials (Trials 1 and 3) and one Phase 2 clinical trial (Trial 2) of patients with CABP. These studies included a single Phase 3 trial in CABP patients (Trial 1) and two Phase 3 trials in ABSSSI patients (Trials 2 and 3). A total of 1023 patients were treated with NUZYRA® (828 patients in Trial 1 and 495 in Trials 2 and 3) and 1020 patients were treated with only oral NUZYRA. In trials 2 and 3, patients were treated with NUZYRA® or with a tetracycline-class antibacterial drug given either orally or parenterally. In Trial 1, eight deaths (2%) occurred in 388 patients treated with NUZYRA® as compared to four deaths (1%) in 388 patients treated with moxifloxacin. All deaths, in both treatment arms, occurred in patients ≥65 years of age. The causes of death varied and included worsening and/or complications of infection and underlying conditions. The cause of the mortality imbalance has not been established (see Warnings and Precautions (5.1)).

**Clinical Adverse Reactions and Adverse Reactions Leading to Discontinuation**

Clinical adverse reactions that occur in ≥2% of patients treated with NUZYRA® include:

- Mortality imbalance
- All-cause mortality
- Inhibition of Bone Growth
- Tetracycline-Class Effects

**Adverse Reactions Occurring in ≥2% of Patients Receiving NUZYRA® in Trial 1**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>N = 325</th>
<th>N = 325</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Constipation</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Increased hepatic aminotransferase activity</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Gamma-glutamyl transferase increased</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>Transaminase increased</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Blood pressure decreased</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Blood pressure increased</td>
<td>2%</td>
<td>3%</td>
</tr>
</tbody>
</table>
NUZYRA® (omadacycline) injection for intravenous use

NUZYRA® (omadacycline) tablets, for oral use

Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation in the pool of ABSSSI trials, serious adverse reactions leading to discontinuation by dose level in the Phase 3 trials and selected adverse reactions that occurred at a frequency of greater than or equal to 1% in all trials are listed below.

Table 5: Adverse Reactions Occurring in ≥2% of Patients Receiving NUZYRA in Pooled Trials 2 and 3

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>NUZYRA (N = 491)</th>
<th>Linezolid (N = 649)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>219</td>
<td>87</td>
</tr>
<tr>
<td>Headache</td>
<td>40</td>
<td>17</td>
</tr>
<tr>
<td>Asthenia</td>
<td>30</td>
<td>14</td>
</tr>
<tr>
<td>Infusion site reactions</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>27</td>
<td>20</td>
</tr>
<tr>
<td>Anemia</td>
<td>14</td>
<td>13</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Anorexia</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Injection site infection</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

In Trial 3, which included the oral loading dose of NUZYRA, 60 (12%) patients experienced nausea and 27 (5%) patients experienced vomiting in NUZYRA treatment group compared to 32 (5%) patients experienced nausea and 26 (4%) patients experienced vomiting in the comparator group. One patient (0.3%) in the NUZYRA group discontinued treatment due to nausea and vomiting.

In Trial 3, which included the oral loading dose of NUZYRA, 111 (30%) patients experienced nausea and 67 (18%) patients experienced vomiting in NUZYRA treatment group as compared to 28 (8%) patients experienced nausea and 11 (3%) patients experienced vomiting in the comparator group. One patient (0.3%) in the NUZYRA group discontinued treatment due to nausea and vomiting.

In Trial 1, which included the oral loading dose of NUZYRA, 60 (12%) patients experienced nausea and 27 (5%) patients experienced vomiting in NUZYRA treatment group compared to 32 (5%) patients experienced nausea and 26 (4%) patients experienced vomiting in the comparator group. One patient (0.3%) in the NUZYRA group discontinued treatment due to nausea and vomiting.

Infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling and skin induration, flu-like symptoms, headache, somnolence, and asthenia are reversible and generally improve over time.

Overdosage: No information on the presence of omadacycline, the effects on the breastfed infant or the effects on milk production. Tetracyclines are excreted in human milk. However, the extent of absorption of tetracyclines, including omadacycline, by the breastfed infant is not known.

There are a number of antibiotic drug options available to treat CABP and ABSSSI in lactating women for serious adverse reactions, including tooth discoloration and inhibition of bone growth; advise patients that breastfeeding is not recommended during treatment with NUZYRA and for 4 days (based on half-life) after the last dose.

Females and Males of Reproductive Potential

The limited available data of NUZYRA use in pregnant women is insufficient to determine the risk of major birth defects and miscarriage. Animal studies indicate that administration of omadacycline during pregnancy resulted in fetal deaths at oral dosages equal to or less than 1/3 the plasma prothrombin activity, patients who are on anticoagulant therapy.

Drug Interactions

Overdosage: No information on the presence of omadacycline, the effects on the breastfed infant or the effects on milk production. Tetracyclines are excreted in human milk. However, the extent of absorption of tetracyclines, including omadacycline, by the breastfed infant is not known.

There are a number of antibiotic drug options available to treat CABP and ABSSSI in lactating women for serious adverse reactions, including tooth discoloration and inhibition of bone growth; advise patients that breastfeeding is not recommended during treatment with NUZYRA and for 4 days (based on half-life) after the last dose.

Females and Males of Reproductive Potential

The limited available data of NUZYRA use in pregnant women is insufficient to determine the risk of major birth defects and miscarriage. Animal studies indicate that administration of omadacycline during pregnancy resulted in fetal deaths at oral dosages equal to or less than 1/3 the plasma prothrombin activity, patients who are on anticoagulant therapy.

The plasma prothrombin activity, patients who are on anticoagulant therapy.

Drug Interactions

Overdosage: No information on the presence of omadacycline, the effects on the breastfed infant or the effects on milk production. Tetracyclines are excreted in human milk. However, the extent of absorption of tetracyclines, including omadacycline, by the breastfed infant is not known.

There are a number of antibiotic drug options available to treat CABP and ABSSSI in lactating women for serious adverse reactions, including tooth discoloration and inhibition of bone growth; advise patients that breastfeeding is not recommended during treatment with NUZYRA and for 4 days (based on half-life) after the last dose.
ACEP just released an expanded version of its emPOC app, and now it includes many more helpful bedside tools and the popular COVID-19 Field Guide. Free for ACEP members, this app is available on iTunes and Google Play.

What are these bedside tools?
ACEP recruited top experts to develop tools our members can trust and deploy in the clinical setting. The evidence-based clinical content provided in these tools ensures that you are providing the best possible care to the patients in your emergency department. You may already be utilizing these tools in the desktop format (www.acep.org/pointofcaretools), but adding them to the emPOC app provides access while working offline or dealing with an inconsistent internet connection.

**NEW**
COVID-19 Field Guide Management of COVID-19 in the ED

**NEW**
Autism Spectrum Disorder Manage Autism Spectrum Disorder Patients in the ED

**AFIB:** Atrial Fibrillation and Flutter

**MAP:** Acute Pain

**BUPE:** Buprenorphine Use in the ED

**BEAM:** Bariatric Examination, Assessment, and Management

**DART:** Treatment of Sepsis and Septic Shock

**ARD:** Agitation in the Elderly

**ICARE2:** Suicide Assessment

**BUPE:** Buprenorphine in the ED

**BEAM:** Bariatric Examination Assessment and Management

**ASD:** Autism Spectrum Disorder

**2020 ACEP NOW October 2020 The Official Voice of Emergency Medicine**
Do you have a license to make change?

In the face of the pandemic, resilience is the power to make decisions.

At Vituity, we believe that the license to act—coupled with dedicated wellness and personal resources—is critical for clinician resilience, and the resiliency of our healthcare delivery system as a whole.

Learn more at vituity.com/resilience.
(Don’t) Let the Air Out

What’s the best intervention for primary spontaneous pneumothorax?

by Ryan Patrick Radecki, MD, MS

There are always times when our attempts to educate individual patients on evidence-based medicine fall short. This leads to a range of acceptable practice variation, with each clinician making their best judgment regarding the care of a patient. This variation is on impressive display with respect to the management of primary spontaneous pneumothorax (PSP).

The options for treatment of PSP range from hospitalization after the placement of a large-bore chest tube to outpatient management with naught but close follow-up. These could all be considered reasonable options absent high-quality data regarding the safety of any individual approach. But recently, researchers have provided several pieces of clarifying evidence.

The management of an otherwise stable but symptomatic patient with PSP typically boils down to a few key decisions. First, is any intervention required? Secondly, if so, what sort of intervention: standard chest tube, narrow-bore chest tube, or aspiration? Finally, should a patient be discharged home or remain in the hospital for observation?

Historical Data

The historical data are best summarized in an Annals of Emergency Medicine article by Mummadai et al., which recently performed a systematic review and network meta-analysis. These authors collated 12 studies, accounting for 281 patients, and applied statistical techniques in an attempt to compare three strategies for intervention: large-bore chest tube (~14 French), narrow-bore (~14 French), or needle aspiration. The authors defined the success of a strategy in terms of resolution of symptoms, adequate lung re-expansion, and the ability for discharge from the emergency department.

Following the applicable statistics, the authors reached only one solid conclusion: the large-bore chest tube is clearly the least preferable of the options. Within the bounds of their combined small sample, the large-bore chest tube was certainly successful at management. However, that strategy was also associated with higher complication rates than the equally successful but safer narrow-bore tube. Needle aspiration, on the other hand, was neither obviously superior nor inferior. The latter strategy lacked the immediate success of the others, primarily due to diminished re-expansion, but had the advantage of being associated with far fewer complications than its competitors.

New Data

Published in the months following that review, however, two additional trials comprising 932 patients have now been added to this sparse body of evidence, providing further insight. The first of these trials is arguably the more important of the two:

As it turns out, “doing nothing” is nearly as good as, and maybe even better than, doing something. Of those randomized to conservative management, 66.6 percent completed follow-up without undergoing a procedure for their pneumothorax. At the eight-week follow-up for the primary outcome, 94.4 percent of those managed conservatively had full lung re-expansion, compared with 98.8 percent of those who underwent intervention. However, this small advantage in radiographical resolution is offset by multiple resource- and patient-oriented outcomes favoring conservative management.

The latter strat- egy lacked the immediate success of the others, primarily due to diminished re-expansion, but had the advantage of being associated with far fewer complications than its competitors.

Additional procedures.

Conclusions

Combining all the evidence from the systematic review and these trials, a few consistent points appear to emerge. The vast majority of patients presenting with a primary spontaneous pneumothorax do not need to be hospitalized but can be safely managed as outpatients following initial assessment and interventions, if indicated. If an intervention is necessary, the smallest-bore chest tube is preferred, and this may include a strategy in which a patient is discharged with devices designed for ambulatory management in place. Most important, these data indicate that nonintervention strategy is sound and reasonable in many instances. The pneumothorax is not a medical emergency and can be managed by ambulatory means.

The opinions expressed herein are solely those of Dr. Radecki and do not necessarily reflect those of his employer or academic affiliates.

References

Mistakes Are Harsh Teachers

No one can avoid all mistakes, but we can minimize and learn from ours

by BENJAMIN THOMAS, MD

“The hardest thing about being a doctor is that you learn best from your mistakes, mistakes made on living people.”

—Dr. Karen Delgado

In emergency medicine, no one ever wants to make a mistake. We assume worst first because at any minute a life could be at stake. As a resident, I was no stranger to making some mistakes. I had cases with bad outcomes, yet the impact of the cases seemed to always be shielded by the umbrella of working with another attending. I don’t think I ever appreciated how high the stakes were until my name was the sole one on the chart. My first “miss” as an attending made me understand the gravity of even the smallest decisions I make as a physician.

The patient was a middle-aged woman with a history of chronic pain, fibromyalgia, and bipolar disorder who presented with constipation, two episodes of nonbloody and nonhilarious vomiting, and diffuse abdominal pain. She was taking an oral opioid around the clock for pain. Her last bowel movement was the night prior, and she was tolerating liquids. On exam, she was mildly tender to palpation throughout, and her abdomen was slightly distended. My initial thought was that she was suffering from an opioid-induced ileus. I considered a small bowel obstruction, but she was still passing gas, tolerating oral intake, and having bowel movements. Her exam wasn’t worrisome, and she didn’t have any concerning signs of a deeper infection.

Her labs were reassuring, and she had a mildly tender, ureter, and bladder test that seemed consistent with an ileus. She remained in the emergency department for some hours and, after a few attempts, could not have a successful bowel movement. I discharged her home with return precautions. Several hours later, she came back in distress. A subsequent CT scan showed a high-grade obstructed volvulus with perforation and a large amount of intraperitoneal air. She was rushed to the operating and had almost 70 cm of necrotic bowel removed. She had a prolonged and complicated hospital course. She would ultimately survive and leave the hospital, but her life was never the same after.

I was devastated after hearing the news of this case. I kept thinking I shouldn’t have let her go. At that point, I was a year out of residency and had no outcomes like this. My confidence was crushed, and I needed to find a way to rebuild. An attending once told me that I would make more mistakes than I could remember and would be named in at least one lawsuit in the course of my career. I remember being skeptical of this as a resident—more so at the notion of making so many mistakes rather than being sued. Of course, no one can expect a physician to make the right decision 100 percent of the time. To err is to be human, of course.

What I now find more important is the way in which we address and mitigate our mistakes. Dr. Jerome Groopman poignantly said, “Every doctor makes mistakes in diagnosis and treatment. But the frequency of those mistakes, and their severity, can be reduced by understanding how a doctor thinks.” We gain expertise not only through sustained practice over time but also by receiving feedback that helps us understand technical errors, bias, and misguided diagnosis. Self-aware physicians learn to admit to their mistakes, analyze them, and keep them accessible at all times.

I can now look back at this case and understand that my encounter with this patient was fraught with bias. From premature closure to anchoring, there were so many mental short-cuts taken that could have been avoided. As emergency physicians, we are especially susceptible to cognitive errors and bias. The emergency department is full of land mines that can distract us, be it abrupt traumas, nursing orders, code blues, or belligerent patients, to name a few. One study noted that health care professionals in the emergency department were interrupted 30 times on average in a three-hour work period. Despite our work environment, there are a number of ways to avoid errors like this in the emergency department. Asking simple questions such as:

• Am I feeling fatigued right now?
• Was this patient handed off to me?
• Have I effectively ruled out must-not-miss diagnoses?

More formal checklists can help prevent diagnostic errors.3

We often learn best from our mistakes, yet in our line of work, the cost of mistakes can be high. This was a practice-changing event for me and one that I will likely never forget. I hope to keep my future mistakes to a minimum but appreciate that through these mistakes, I will become a better physician. ♦

References


The Official Voice of Emergency Medicine
Litigation in the Era of COVID-19
How physicians can protect against liability during the pandemic

by GITA PENS

Physicians are used to seeing billboards and daytime television advertisements for plaintiff’s attorney firms. Our reactions to these ads usually range from indifference to annoyance. But recently, plaintiff’s attorneys were called out publicly for advertising actively soliciting COVID-19 malpractice cases. A few of these advertisements were shared widely on social media, with resultant incensed commentary from physicians and the public alike. This eventually forced a retraction and public apology from at least one firm.

Health care workers, particularly physicians, are preyed upon by unethical attorneys all the time, yet we rarely raise any public outcry. Why did this cause such vocal protest?

Physicians are caring for COVID-19 patients while risking our own health and the health of our families, often with inadequate personal protective equipment. We are being strained in unprecedented ways. Also, the adverse outcomes in this pandemic are largely out of our control. Treatment options for COVID-19 are new and unproven. The virus has an unpredictable course, and unexpected deaths are common. Scarcity of resources can also affect outcomes. Surge plans may leave emergency physicians working in the ICU or medical floor or managing improvised pop-up ICUs in their departments. Many external factors ensure that undesirable outcomes will be increased overall—and yet, these advertisements suggest that physicians, as always, should be the scapegoats when anything goes wrong.

Consider this hypothetical case: A middle-aged man presents with influenza-like symptoms in the setting of the COVID-19 pandemic. He is febrile, with otherwise normal vitals. A chest X-ray is normal. A COVID-19 test is sent but will not return for several days. He is discharged to home, with return precautions and outpatient follow-up. At home, he worsens. He returns to the emergency department several days later and dies after a cardiac arrest at the time of intubation. Setting aside the grief of the patient’s family and the physician at this terrible outcome, can the physician be sued?

Can the physician be held liable for malpractice?

Tricky Question of Liability
Yes, the physician can be sued, even in states with new liability protections in place that relax the legal standard for malpractice. However, whether that physician is held liable is determined by a jury at the time of trial. Juries eventually determine liability using the “standard of care” which is defined differently in different states and generally means what a minimally competent and similarly trained physician might do in circumstances similar to the one in question. In many states that have enacted liability protections, the physician is immune from liability except in the setting of “gross negligence or willful misconduct.” These terms also are defined differently in each state, but in general, willful misconduct means a physician intentionally harmed someone, while gross negligence is showing wanton disregard for basic care of human beings.

The actual degree of liability protection varies from state to state, so it is important to know the current law where you practice. Some states are granting immunity to any care rendered during the pandemic, while others apply it only to COVID-19 patients. Other states extend this immunity for activities related to “medical countermeasures” against the ongoing COVID-19 pandemic. This is not thought to protect physicians from usual care rendered during COVID-19, but this will be considered on a case-by-case basis. In general, the liability immunity applies to those involved in the development, manufacture, testing, distribution, administration, and use of medical countermeasures described in the declaration. However, you should always document that you are potentially caring for COVID-19 patients in case the act might apply in some way in your defense should a lawsuit be filed.

Even though lawsuits still may be filed, these new protections are potentially helpful. Plaintiff’s attorneys know that any case related to care during this time will be a very steep climb for them, and hopefully, this will be a significant deterrent. Juries are unlikely to forget the esteem that the public holds health care workers in right now, even if a trial is years away. These protections are not ironclad, but they may give you more peace of mind.

In states with no additional protections in place, the worst-case scenario is that a physician is held to the usual standard of care. But it is critical to remember that the standard of care changes with context and circumstances. The circumstances right now are pandemic circumstances, jurists will take that into account.

Protection in Documentation
The best advice I have for risk mitigation—other than taking good care of your patients—is to document well. COVID-19 care documentation is required to even consider application of the PREP Act. Be sure to explain any deviations from usual practice that are due to the pandemic. Document if hospital capacity or concern for the nosocomial transmission of COVID-19 factored into any decisions to discharge or admit a patient. Make sure your patients understand their discharge instructions and return precautions, and document that as well. Even for non-COVID-19 patients, consider charting a statement such as “...as this patient was seen during the COVID-19 pandemic, they were queried about fever, cough, [etc.]...” This makes it clear that the patient is being seen at a time when hospital capabilities may not be at their norm.

There are other important ways to protect yourself legally. If you find yourself practicing outside of your usual environment, it is crucial that you are in touch with your insurance carrier to apprise them of those changes. You want to be assured in writing that you have coverage extending to any new activities.

Last spring, many physicians volunteered in hard-hit areas across state lines; some physicians even came out of retirement to help. In these situations, there are some federal protections against liability, and some states have their own sets of protections for volunteers. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act became active law; it includes Good Samaritan language that provides additional federal liability protections. Physicians and other health care professionals who provide volunteer medical services during the pandemic will not be held liable for care relating to COVID-19—again, except in cases of gross negligence or willful misconduct. The federal law supersedes any state laws that are less protective.

While all of this is helpful for volunteers, do not rely exclusively on these protections. You must have adequate malpractice insurance coverage for your volunteer activities. If a lawsuit is filed, it is crucial that you are covered, as an attorney will be required to defend your case and demonstrate whether these acts even apply. Attorney’s fees will be thousands of dollars if paid out of pocket. It is much better to have proof of insurance coverage in writing, likely through your volunteering program. It is also important that your license is fully in order to practice in whatever state you may find yourself working.

Take proactive steps to protect yourself the best you can. Then go back to taking good care of your patients, knowing you have taken the necessary steps to take care of yourself.
Honorary Membership Award
Jane Scott, ScD, MSN
Dr. Scott has worked in emergency care settings for years, starting as a nurse in the Duke University emergency department, the Hillsborough, North Carolina, Volunteer EMS squad, and the Johns Hopkins emergency department as a nurse practitioner. After obtaining a doctorate from Johns Hopkins School of Public Health, Dr. Scott joined the Agency for Health Research and Quality as a program officer. In 2009, Dr. Scott joined the National Institutes of Health (NIH) as director of the office of research training in the division of cardiovascular sciences at the National Heart, Lung, and Blood Institute (NHLBI). In 2008, she started to create the NHLBI K12 program in emergency medicine research. Since then, she has managed the K12 program and worked extensively with the emergency medicine researchers.

Honorary Membership Award
Hugh Dean Wilkerson, JD, MBA, CAE
A native Arkansan, Mr. Wilkerson has spent most of his life in Texas. He earned a bachelor’s degree at the University of Arkansas, MBA from the University of California at Berkeley, and a law degree from the University of Texas.

In the 1980s, Mr. Wilkerson practiced corporate law with a large Dallas law firm and served on the city council and as mayor pro tem of Coppell, Texas. In 1990, Mr. Wilkerson became the general counsel of Mothers Against Drunk Driving (MADD). Three years later, he became the national CEO of MADD.

He left MADD to become the executive director of ACEP. Being part of the EM family has been the most enjoyable period of his 40-year career.

Innovative Change in Practice Management Award
Rahul Sharma, MD, MBA, FACEP
Dr. Sharma is professor and chair of the department of emergency medicine at Weill Cornell Medicine in New York City. He is also the emergency physician in chief at NewYork-Presbyterian/Weill Cornell Medical Center. In addition, he serves as chief and medical director for the NewYork-Presbyterian EMS enterprise and in several other executive roles, including as a member of the New York State Board for Medicine and as president of the NewYork-Presbyterian Hospital Medical Board.

Since 2016, he has founded and launched several telemedicine programs including the award-winning Emergency Department Telehealth Express Care and the Center for Virtual Care. Most recently, he led efforts to transform emergency medicine health care delivery in response to the COVID-19 pandemic.

Outstanding Contribution in Research Award
Alan E. Jones, MD, FACEP
Dr. Jones completed residency and a clinical research fellowship at Carolinas Medical Center in Charlotte, North Carolina, in 2001. He was on the faculty of the department of emergency medicine at Carolinas Medical Center for 10 years. He moved to the University of Mississippi Medical Center (UMMC) in 2011 and became chair of the department of emergency medicine in 2013. In 2017, he became the vice-chair of the council of clinical chairs, and in 2019, he was named chief operations physician at UMMC.

Dr. Jones has served as the executive medical director of Mississippi TelEmergency, executive medical director of the UMMC Mississippi Critical Care Organization, and the chief telehealth officer for the UMMC Center for Telehealth. In 2020, Dr. Jones stepped down as chair and was named assistant vice-chancellor for clinical affairs of the UMMC Health System.

Outstanding Contribution in EMS Award
James M. Atkins, MD
Dr. Atkins graduated from the University of Texas Southwestern Medical School in Dallas and performed his internship and residency in internal medicine and his subspecialty training in cardiology at Parkland Memorial Hospital in Dallas.

In 1972, he was asked to supervise part-time the internal medicine portion of the emergency department at Parkland Hospital, which he did for five years when he convinced the system to hire the first full-time staff for the emergency department. He has been involved in the American Heart Association (AHA) at the national and local levels, as well as with the American College of Cardiology Emergency Care Committee.

Dr. Atkins was medical director of the premedic system in Dallas County for 27 years. He has been a professor of internal medicine and emergency medicine at the University of Texas Southwestern Medical School and works as a cardiologist at Parkland Memorial Hospital.

The symposium is designed to address the continuum of care of the injured person. Topics will be relevant for physicians, nurses, EMTs and allied health providers who work together for interdisciplinary cooperation. While the online format is new, the caliber of presenters and quality of the content remains the same. Topics will include:

- Current and future training of trauma care providers in civilian and military settings
- Vascular control and repair modalities for the ED, OR, and hybrid suite
- New transfusion therapies for trauma and the ICU
- New concepts in VTE in the trauma patient
- Adversity and building resistance in the trauma setting

For topics, speakers, CME credits and to register, visit DetroitTrauma.org
5 Tips on Testicular Torsion

Don’t let myths lead to misdiagnosis

by ANTON HELMAN, MD, CCFP(EM), FCFP

A 20-year-old healthy man arrives at the emergency department at 4 a.m. complaining of one hour of excruciating right testicular pain that radiates to his right lower quadrant and right flank. He’s been vomiting repeatedly. He has had no preceding lower urinary tract symptoms. Vitals are normal except for a heart rate of 115. His right testicle appears swollen with a horizontal high-riding lie and is exquisitely tender to palpation. The cremasteric reflex is absent on the right side.

This is a relatively straightforward case for the diagnosis of testicular torsion, but unfortunately most cases of testicular torsion are not so clear-cut; the classic symptoms and signs often are not present. That is why 30 percent of the cases with failed

CONTINUED on page 30

CLASSIFIEDS

LIVE. WORK. PLAY.

Patient centered. Physician centric. Quality focused. Culture driven. This is how our physicians describe us. If you’re ready to join a company where your contribution as a patient-focused team member is valued, elevate your career with American Physician Partners. Now with 150+ opportunities across the country, you can LIVE, WORK and PLAY with the best.

appartners.com | 855.246.8607 | careers@appartners.com
ENVISION PHYSICIAN SERVICES HAS GIVEN ME ...

THE SUPPORT TO EXCEL AND
THE AUTONOMY TO THRIVE

Richard T. Logue, MD

RICHARD LOGUE, MD, FACEP
EMERGENCY MEDICINE

Featured Director Positions

Sentara Careplex Hospital
Hampton, Virginia

Southern Regional Medical Center
Riverdale, Georgia

Rio Grande Regional Hospital
McAllen, Texas

UCF Lake Nona Medical Center
Orlando, Florida

McDonough District Hospital
Macomb, Illinois

855.514.0930
EVPS.com/ACEPNow

Talk with our physician leadership virtually at ACEP20

Envision PHYSICIAN SERVICES
While COVID-19 has created unprecedented challenges this year, TeamHealth has remained strong. For more than 40 years, our stability and national resources help our clinicians deliver the best possible patient care. TeamHealth is proud to be one of the largest integrated care providers in the country, driven by our commitment to quality and safety.

We look forward to being a part of ACEP20 Unconventional conference. Connect with us virtually at teamhealth.com/acep20!
Penn State Health, Hershey PA, is expanding our health system. We offer multiple new positions for exceptional physicians eager to join our dynamic team of EM and PEM faculty treating patients at the only Level I Adult and Level I Pediatric Trauma Center in Central Pennsylvania.

What We’re Offering:
• Salaries commensurate with qualifications
• Sign-on Bonus
• Relocation Assistance
• Retirement options, Penn State University Tuition Discount, and so much more!

What We’re Seeking:
• Emergency Medicine trained physicians with additional training in any of the following: Toxicology, Ultrasound, Geriatric Medicine, Pediatric Emergency Medicine, Research
• Completion of an accredited Residency Program.
• BE/BC by ABEM or ABOEM

What the Area Offers:
We welcome you to a community that emulates the values Milton Hershey instilled in a town that holds his name. Located in a safe family-friendly setting, Hershey, PA, our local neighborhoods boast a reasonable cost of living whether you prefer a more suburban setting or thriving city rich in theater, arts, and culture. Known as the home of the Hershey chocolate bar, Hershey’s community is rich in history and offers an abundant range of outdoor activities, arts, and diverse experiences. We’re conveniently located within a short distance to major cities such as Philadelphia, Pittsburgh, NYC, Baltimore, and Washington DC.

For more information please contact:
Heather Peffley, PHR FASPR at: hpeffley@pennstatehealth.psu.edu
testicular salvage can be attributed to mistri-agnosis, with another 13 percent to delays in treatment after the diagnosis has been made.1

1. Time counts, but salvageability is possible more than 48 hours after symptom onset. Testicular torsion is a surgical emergency regardless of the time of onset. The spermatic cord twists, leading to impaired blood flow to the testicle, which causes ischemia and tissue necrosis. The degree of twisting and duration of symptoms are prognostic factors of testis salvage, with 96 percent success rates when perfusion is restored within four hours. Salva-

gage is less than 10 percent if interventions are delayed for more than 24 hours. Nonetheless, salvageability has been shown beyond 48 hours after symptom onset, contrary to the historical teaching that symptoms of more than 24 hours are inconsistent with salvageable tissue. In delayed cases that are salvageable, there may be intermittent, rather than continuous, twisting of the spermatic cord, allowing reperfusion of the testicle. Therefore, it is incumbent on emergency physicians to manage all acute scrotal cases as surgical emergencies, even if the time from onset to presentation exceeds 24 hours.

2. Testicular torsion can occur at any age. Testicular torsion has a bimodal distribution: first year of life and in adolescence. I’ve had urologists tell me emphatically that testicu-

lar torsion does not occur in patients older than 40 years of age. Nonetheless, in a study of 469 closed malpractice claims with indem-

nity payment, the mean age was 23 years and there were four patients over the age of 40.4 The literature is rife with case reports of older patients with surgically confirmed testicular torsion.5,6

3. Testicular torsion can present with minimal, intermittent, or no scrotal pain. While a sudden onset of severe, unrelent-

ing unilateral scrotal pain radiating to the abdomen and/or flank is typical, the pain of testicular torsion can also be minimal or inter-

mittent—again, attributed to intermittent twisting and untwisting of the spermatic cord that occurs in some cases.7 These “pain honey-

moons” may partially account for poor clinical outcomes. As many as 20 percent of patients with testicular torsion present with isolated lower abdominal pain.8 In light of this, all male patients presenting with lower abdomi-

nal pain should have a genital examination regardless of the time of onset. Studies report varying sensitivi-

ties as low as 60 percent and odds ratios (ORs) from 4.8 to 27.8.9,10 While the presence of an elevated testicle (OR=58.8) and a horizontal testicular lie increase the likelihood of testicular torsion, it is often difficult to palpate the testicle only, thereby determining its position relative to other adjacent structures.9 Scrotal erythema, edema, and testicular swelling are commonly reported in patients with torsion. However, these findings are also commonly found in patients with epididymitis and torsion of the appendix testis.10 Prehn’s sign is the relief of pain with elevation of the testicle, historically thought to be common in patients with epididymitis. This physical examination finding does not reliably distinguish epididymitis from torsion. One cross-sectional study of 120 patients found the Prehn’s sign was present in 91 percent of patients with torsion and 21 percent of those with epididymitis.11

In 2013, an attempt at combining clinical features of testicular torsion in a clinical decision tool for the diagnosis of testicular torsion yielded the TWIST (Testicular Workup for Ischemia and Suspected Torsion) score. While this score showed a 100 percent posi-

tive predictive value when all clinical findings were present, potentially obviating the need for Doppler ultrasound imaging confirmation of the diagnosis, it failed to show adequate negative predictive value in ruling out the di-

agnosis clinically.12 Hence, all patients with any suspicion for testicular torsion should have urgent Doppler ultrasound imaging and/or urological consultation.

HyperRAB®

Rabies Immune Globulin (Human)

These highlights do not include all the information needed to use HYPERRAB® safely and effectively. See full prescrib-

ing information for HYPERRAB.

HYPERRAB (rabies immune globulin (human)) solution for infiltration and intramuscular injection

Initial U.S. Approval: 1974

---------------INDICATIONS AND USAGE---------------

HYPERRAB is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use

Persons previously immunized with rabies vaccine that have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

-------------------DOSEAGE AND ADMINISTRATION-------------------

For infiltration and intramuscular use only.

Administer HYPERRAB within 7 days after the first dose of rabies vaccine.

Postexposure prophylaxis, along with rabies vaccine, after suspected exposure to rabies

HYPERRAB 20 IU/kg body weight OR 0.0665 mL/kg body weight Single dose

• Administer as soon as possible after exposure, preferably at the time of the first rabies vaccine dose.

• Infiltrate the full dose of HYPERRAB thoroughly in the area around and into the wound(s), if anatomically feasible.

• Inject the remainder, if any, intramuscularly.

5. Doppler ultrasound has significant limitations in the diagnosis of testicular torsion. If clinical features cannot rule out torsion, can a Doppler ultrasound? Typically, Dop-

pler ultrasound findings for testicular torsion include an enlarged, hyperemic testicle; decreased Doppler flow to the parenchyma of the testicle itself; and a “whirlpool sign” (a spiral-like pattern of the spermatic cord twist-

ing).13,14 Unfortunately, the test characteristics of Doppler ultrasound are far from perfect, and it is subject to false negatives; the sper-

matic cord may untwist while the ultrasound is being performed and re-twist afterwards.
Alternatively, a partially-torsed testicle may exhibit arterial flow but no venous flow, or it may show an abnormal high-resistance pattern of arterial flow. The sensitivity of Doppler ultrasound ranges from 88 to 100 percent. When ultrasound is nondiagnostic and the clinical presentation remains concerning, urology consultation remains warranted. The gold standard for diagnosis and exclusion of testicular torsion is surgical exploration.

**Conclusion**

Next time you are faced with a patient with acute lower abdominal and/or scrotal pain, consider the diagnosis of testicular torsion regardless of age. Understand that the differential diagnosis includes torsion of the appendix, diverticulitis, appendicitis, ileal intussusception, and intussusception of the colon. Remember that testicular torsion is surgical emergency. Remember that the presence of a cremasteric reflex does not rule out testicular torsion and that all clinical characteristics and even Doppler ultrasound have significant limitations in making or excluding the diagnosis. Urological consultation should always be obtained in equivocal cases.

**Special thanks to Dr. Natalie Wolpert and Dr. Yonah Krakowsky for their expert contributions to the EM Cases podcast that inspired this article.**

**References**


**Indication and Usage**

HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

**Limitations of Use**

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

**Important Safety Information**

**For infiltration and intramuscular use only**.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.

Please see brief summary of Prescribing Information on adjacent page or visit HyperRAB.com for full Prescribing Information.
The first and only high-potency human rabies immune globulin (HRIG) that offers:

- The volume of medication administered in a total dose, potentially resulting in fewer injections
- The concentration of rabies antibodies per mL at the wound site

When protecting your patients with HRIG

DELIVER MORE OF THE TOTAL DOSE AT THE WOUND SITE.

HyperRAB®
(rabies immune globulin [human]) 300 IU/mL

The first and only high-potency human rabies immune globulin (HRIG) that offers:

1/2
2X

1/2
2X

Introducing greater dosing convenience with a new 3-mL (900-IU) vial

When protecting your patients with HRIG

DELIVER MORE OF THE TOTAL DOSE AT THE WOUND SITE.

HyperRAB®
(rabies immune globulin [human]) 300 IU/mL

The first and only high-potency human rabies immune globulin (HRIG) that offers:

- The volume of medication administered in a total dose, potentially resulting in fewer injections
- The concentration of rabies antibodies per mL at the wound site

HyperRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

HyperRAB is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Please see Important Safety Information and brief summary of Prescribing Information for HyperRAB on adjacent pages, or visit www.HyperRAB.com for full Prescribing Information.

For more information, visit www.HyperRAB.com

© 2020 Grifols  All rights reserved  March 2020  US-HB3-2000016